Northwest Biotherapeutics, Inc. (BST:NBYB)

Germany flag Germany · Delayed Price · Currency is EUR
0.2400
+0.0400 (20.00%)
At close: Jul 23, 2025
20.00%
Market Cap311.92M
Revenue (ttm)1.36M
Net Income (ttm)-79.49M
Shares Outn/a
EPS (ttm)-0.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,215
Average Volume22,959
Open0.1990
Previous Close0.2000
Day's Range0.1990 - 0.2460
52-Week Range0.1730 - 0.4500
Betan/a
RSI55.68
Earnings DateAug 11, 2025

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 25
Stock Exchange Stuttgart Stock Exchange
Ticker Symbol NBYB
Full Company Profile

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.